Osteoporosis in a young woman after 6 years of levonorgestrel administration from intrauterine devices?

Case report OA: closed
⚙ AI-generated summary by qwen3.7-flash, 2026-09-22 ⓘ

A 28-year-old woman developed mild osteoporosis and suppressed estradiol levels after six years of levonorgestrel intrauterine device use, suggesting that long-term exposure may reduce bone density in young women.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-12 · read from full text ⓘ

This case report describes a 28-year-old woman who developed premenopausal osteoporosis and suppressed estradiol levels after eight years of using a levonorgestrel-releasing intrauterine device for contraception and heavy bleeding. Extensive diagnostic testing excluded secondary causes, linking the bone density loss directly to the contraceptive-induced suppression of the hypothalamic-pituitary-ovarian axis and subsequent estrogen deficit. The patient’s estradiol production normalized rapidly following device removal, supporting the hypothesis that long-term progestin exposure can impair peak bone mass acquisition in young women. Relevance to endometriosis: the device was initially inserted to manage symptoms associated with endometriosis, making this paper centrally about a complication arising from the treatment of endometriosis rather than the disease itself.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

This report describes a young woman who developed dysmenorrhoea at the age of 12. She received a levonorgestrel (LNg)-releasing intrauterine device at the age of 21, and this was replaced twice within 8 years. At the age of 28, she started to have multiple bone and joint pain (predominantly low back pain), which, after intensive diagnostic of blood parameters and bone CT, turned out to result - from a manifest (mild) osteoporosis. Since the woman developed very low (postmenopausal) oestradiol levels during the presence of the gestagen-releasing device and encountered normalisation of oestradiol production after removal, suppression of the hypophysial-ovarian axis is proposed as the cause of both lack of oestradiol and osteoporosis. This poses the question of whether long-term use of such devices in young women may result in reduced bone density in the early phases of life, paving the way to serious osteoporosis at menopause.
Full text 12,067 characters · extracted from oa-html · 4 sections · click to expand

Abstract

This report describes a young woman who developed dysmenorrhoea at the age of 12. She received a levonorgestrel (LNg)-releasing intrauterine device at the age of 21, and this was replaced twice within 8 years. At the age of 28, she started to have multiple bone and joint pain (predominantly low back pain), which, after intensive diagnostic of blood parameters and bone CT, turned out to result – from a manifest (mild) osteoporosis. Since the woman developed very low (postmenopausal) oestradiol levels during the presence of the gestagen-releasing device and encountered normalisation of oestradiol production after removal, suppression of the hypophysial–ovarian axis is proposed as the cause of both lack of oestradiol and osteoporosis. This poses the question of whether long-term use of such devices in young women may result in reduced bone density in the early phases of life, paving the way to serious osteoporosis at menopause.

Background

We believe that this report addresses a major, possibly hidden, long-term health problem. Millions of young women resort to low-dose gestagen from intrauterine devices (IUDs), mini-pills or gestagen depots for contraception.1–3 Some women may lose their ovulatory cycle and thus the normal oestrogen levels instrumental for mature bone development. This case demonstrates that 7 years of suppressed oestrogen production may lead to early osteoporosis. CASE PRESENTATION A young female patient (height 174 cm, weight 57 kg, body mass index 18.8) had a levonorgestrel-releasing IUD (LNg-IUD, releasing initially 20 μg/24 h, and later 11 μg/24 h) inserted for contraception, heavy bleeding and endometriosis in May 1999. At that time, the age of the patient was 21 years. The LNg-IUD was replaced by a new one in June 2002 after she felt uncomfortable with recurring of mid-cycle lower abdominal pain. Medical conditions improved for a period of almost 3 years, but pain re-emerged in March 2005, leading to a second replacement of the LNg-IUD. Repetitive low back pain initiated a careful examination of the spine in 2006. A (preclinical) osteopenia in the lumbar spine, in areas of the left distal radius, and the Ward`s triangle developed. In 2005, early stage osteoporosis was diagnosed in the femoral neck and in areas of the trabecular distal radius by means of dual energy x ray absorptiometry (DXA) and peripheral CT (pQCT). One and 2 year follow-up examinations revealed the same overall stable findings. T-scores ranged from −2.05 to −2.82, and Z-scores were in a range of −1.95 to −2.73. Subsequent basic and differential laboratory testing (serum calcium and phosphate, thyroid stimulating hormone, parathormone, 25-hydroxycholecalciferol, cortisol level and others) ruled out a secondary osteoporosis. The contribution of risk factors such as a BMI <19 and smoking habits (3 cigarettes/day) in the young woman cannot be estimated, but appear minor in the context of the severity of the peak bone loss. A deficit of oestradiol (E2) seemed to be the last parameter in the genesis of osteoporosis that had not been taken into consideration so far. Nevertheless, premenopausal osteoporosis was evident during IUD application (see fig 1). Continuing gynaecological and endocrinological examinations revealed a reduced ovarian function with a relative oestrogen deficit. Hormonal parameters were analysed several times during the 8-year period of LNg-IUD insertion. Oestradiol concentrations were not higher than 8–59 pg/ml during the whole period of LNg-IUD exposure. Before final removal of the LNg-IUD, a blood sample was taken on 8 March 2007 and this showed an oestradiol concentration of 17 pg/ml, which was clearly in the range for a postmenopausal woman (see fig 1). The patient decided to have the IUD removed for a trial period. Shortly after the IUD removal in March 2007, oestradiol concentrations of the patient rose to 193 pg/ml (17 days after removal). Subsequent measurements over the next months and years showed concentrations within the typical range of a normal ovulatory menstrual cycle (eg, on 28 May 2008, the day before the ovulation; see fig 1). OUTCOME AND FOLLOW-UP Follow-up examinations at 1 year and 2 years revealed the same overall stable findings. T-scores ranged from −2.05 to −2.82, and Z-scores ranged from −1.95 to −2.73 (see Case presentation).

Discussion

We here report on a young woman who developed premenopausal osteoporosis within an 8-year treatment period with a levonorgestrel-releasing IUD. Secondary osteoporosis could be excluded on the basis of intensive medical examination, anamnesis and laboratory testing. Genetic factors were unlikely: The occurrence and development of the osteoporosis, as well as laboratory testing, did not indicate a contribution of genomics. However, not all genomic factors responsible for osteoporosis could be excluded,4 the responsible technology not yet being available. Most likely, the condition was caused by an oestrogen deficit induced by permanent exposure to levonorgestrel. Indeed, several measurements of oestradiol (E2), progesterone and luteinising hormone concentrations all indicated that low (postmenopausal) levels of oestradiol were present during exposure to the IUD. Within days after removal of the IUD the patient experienced an increase of oestrogen and regained cyclic oestradiol production typical for an unimpaired ovulatory cycle. While oestrogen concentrations were below 50 pg/ml before IUD removal, the values rose to 193 pg/ml (ie, typical values for the premenopausal phase) after IUD removal (fig 1). To our knowledge this is the first case demonstrating that gestagenes, even when given topically within the uterus, may interfere with the oestrogen production and consequently may cause osteoporosis. It has been shown in the past that subcutaneous depots of medroxyprogesterone acetate may reduce bone mineral density especially in young women.5 Recently, it was demonstrated that levonorgestrel and etonogestrel, released from subcutaneous implants, are associated with a significant reduction in bone mineral density within the following 36 months.6 On the other hand, levonorgestrel administered via an IUD did not cause bone mineral density reduction as compared with an uterine device not releasing gestagenes7,8 or hysterectomy.9 However, the women participating in the latter investigations were clearly older on average than our patient who started using LNg-IUD at the age of 21 years. Indeed, the German Summary of Product Characteristics (SPC) suggests exclusion of young women (nullipara) from LNg-IUD use, and lists back pain and anovulatory cycles as predominant adverse reactions.10 High local concentrations of gestagen in the uterine cavity caused by an LNg-IUD have been confirmed in many studies.11 It is worth recalling that the uterus drains via the vena uterine into the vena cava inferior, and this can reduce a possible first-pass metabolism of levonorgestrel and provides the opportunity for systemic effects. This contention is supported by the results of a small study evaluating the influence of long-term use of progestin-only vaginal rings. Suppression of oestradiol concentrations in a 5-year treatment was rare, but occurred, and it went along with anovulatory cycles.12 Our patient had the IUD changed twice within 8 years of continuing contraception. It appears possible that the decreasing levonorgestrel release from the IUD led to re-initiation of an ovulatory cycle, which in turn caused ovulatory abdominal pain. Consequently, a new IUD was inserted, and this again released relatively high doses of levonorgestrel (initial dose release 20 μg/day) – again suppressing the ovulatory cycle and reducing ovulatory pain, but causing oestrogen deficit and loss of bone mineralisation. LEARNING POINTS In conclusion, we believe that this observation is noteworthy because it demonstrates that gestagenes, even when released from an intrauterine device, may be sufficient to cause suppression of oestradiol production and impair bone density. Although levonorgestrel is assumed to decrease bone mineral density, it can not be taken for granted that physicians prescribing an intrauterine device to young women are informed about this risk; furthermore, it is not mentioned explicitly in any summary of product characteristics, which are the only authoritative information accessible to physicians. Our observation raises general health concerns as osteoporosis in elderly women is becoming a medical issue and care should be taken to avoid interference with the development of normal bone density at younger ages. The case pointed out that lower back pain of the patient acted as a first indicator for her osteoporosis. In order to achieve and maintain a maximum peak bone density, and thus guarantee the lowest possible risk for menopausal women, there should be a careful monitoring – especially of young premenopausal women suffering from back pain – by means of densitometry when using oral or intrauterine levonorgestrel contraceptives. Low doses of gestagen given to young women – even when released locally in utero – may result in long term bone mineralisation deficits and impaired bone mineralisation if ovulatory cycles, and consequently oestradiol production, are lacking. Footnotes Competing interests: none. Patient consent: Patient/guardian consent was obtained for publication.

References

- 1.Petitti DB, Piaggio G, Mehta S, et al. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstet Gynecol 2000; 95: 736–44 [DOI] [PubMed] [Google Scholar] - 2.Scholes D, LaCroix AZ, Ichikawa LE, et al. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women. Contraception 2004; 69: 99–104 [DOI] [PubMed] [Google Scholar] - 3.Scholes D, LaCroix AZ, Ichikawa LE, et al. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 2005; 159: 139–44 [DOI] [PubMed] [Google Scholar] - 4.Hirschhorn JN, Gennari L. Bona Fide genetic associations with bone mineral density. N Engl J Med 2008; 358: 2403–5 [DOI] [PubMed] [Google Scholar] - 5.Monteiro-Dantas C, Espejo-Arce X, Lui-Filho JF, et al. A three-year longitudinal evaluation of the forearm bone density of users of etonogestrel- and levonorgestrel-releasing contraceptive implants. Reprod Health 2007; 4: 11. [DOI] [PMC free article] [PubMed] [Google Scholar] - 6.Cromer BA. Effects of hormonal contraceptives on bone mineral density. Drug Saf 1999; 20: 213–22 [DOI] [PubMed] [Google Scholar] - 7.Halmesmaki K, Hurskainen R, Tiitinen A, et al. A randomized controlled trial of hysterectomy or levonorgestrel-releasing intrauterine system in the treatment of menorrhagia-effect on FSH levels and menopausal symptoms. Hum Reprod 2004; 19: 378–82 [DOI] [PubMed] [Google Scholar] - 8.Ogbonmwan S, Briggs P, Amu O. The oestrogen “sparing” effect of implanon: a case report and review. Eur J Contracept Reprod Health Care 2006; 11: 109–11 [DOI] [PubMed] [Google Scholar] - 9.Bahamondes L, Espejo-Arce X, Hidalgo MM, et al. A cross-sectional study of the forearm bone density of long-term users of levonorgestrel-releasing intrauterine system. Hum Reprod 2006; 21: 1316–9 [DOI] [PubMed] [Google Scholar] - 10.Fachinformation Mirena [summary of product characteristics, Mirena] Pharma BS, Rote Liste Service GmbH – Fachinfo Service, 2007 [Google Scholar] - 11.Devoto L, Fuentes A, Palomino A, et al. Pharmacokinetics and endometrial tissue levels of levonorgestrel after administration of a single 1.5 mg dose by the oral and vaginal route. Fertil Steril 2005; 84: 46–51 [DOI] [PubMed] [Google Scholar] - 12.Brache V, Alvarez-Sanchez F, Faundes A, et al. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants. Contraception 1990; 41: 169–77 [DOI] [PubMed] [Google Scholar]

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-11-15T09:34:25.365398+00:00
pubmed
last seen: 2026-10-08T21:09:02.791371+00:00
unpaywall
last seen: 2026-11-19T08:49:44.633026+00:00